Valion Bio (VBIO) Operating Leases (2021 - 2026)

Valion Bio has reported Operating Leases for 5 years, with the latest figure at $10.0 million in Q2 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $10.0 million in Q2 2026; TTM through Jun 2026 was $10.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $176000.0, down 52.04% from the prior year.
• Operating Leases was $10.0 million for Q2 2026 at Valion Bio, up from $321000.0 in the prior quarter.
• The five-year high for Operating Leases was $10.0 million in Q2 2026, with the low at $176000.0 in Q4 2023.
• Average Operating Leases over 4 years is $1.4 million, with a median of $460500.0 recorded in 2022.
• The largest YoY upside for Operating Leases was 0.2% in 2023 against a maximum downside of 52.04% in 2023.
• Over 4 years, Operating Leases stood at $367000.0 in 2022, then sank by 52.04% to $176000.0 in 2023, then surged by 82.39% to $321000.0 in 2024, then jumped by 3021.81% to $10.0 million in 2026.
• The last three Operating Leases figures came in at $10.0 million (Q2 2026), $321000.0 (Q1 2024), and $176000.0 (Q4 2023), per Business Quant data.